GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Clinical trial NCT06522386 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06522386
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-30
- Primary completion
- 2027-02-28
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.